Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP8 | P22894 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.33 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.33 |
| ▸ | SOAT1 | P35610 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | PKM | P14618 | 1/20 | 0.30 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL543816 | 0.81 | CYP4F2 (0.35) | MMP8ALDH1A1CYP4F2CYP4A11SOAT1 | |
| SCHEMBL8045727 | 0.79 | MMP8 (0.35) | MMP8ALDH1A1CYP4F2CYP4A11KDM4E | |
| SCHEMBL5451691 | 0.78 | MAPT (0.37) | MMP8ALDH1A1CYP4F2CYP4A11KDM4E | |
| SCHEMBL10930331 | 0.78 | CYP4F2 (0.37) | MMP8ALDH1A1CYP4F2CYP4A11SOAT1 | |
| SCHEMBL7828510 | 0.76 | CYP4F2 (0.32) | MMP8CYP4F2CYP4A11 | |
| SCHEMBL578916 | 0.76 | CYP4F2 (0.36) | MMP8ALDH1A1CYP4F2CYP4A11SOAT1 | |
| SCHEMBL1072447 | 0.76 | CYP4F2 (0.36) | MMP8ALDH1A1CYP4F2CYP4A11SOAT1 | |
| SCHEMBL3133963 | 0.76 | CYP4F2 (0.36) | MMP8ALDH1A1CYP4F2CYP4A11SOAT1 | |
| SCHEMBL18759662 | 0.75 | CYP4F2 (0.40) | MMP8ALDH1A1CYP4F2CYP4A11SOAT1 | |
| SCHEMBL16048 | 0.75 | CYP4F2 (0.40) | MMP8ALDH1A1CYP4F2CYP4A11SOAT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7544835-B2 | Carboxylic acid derivative and salt thereof | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2009-06-09 | — | — | US | disclosed |
| US-20040102634-A1 | Carboxylic acid derivative and salt thereof | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2004-05-27 | — | — | US | disclosed |
| EP-1380562-A1 | CARBOXYLIC ACID DERIVATIVE AND SALT THEREOF | Eisai Co., Ltd. (JP) | 2004-01-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040102634-A1 | Carboxylic acid derivative and salt thereof | GPR119, IRS1, SLC5A1 | MMP8 2034/4885ALDH1A1 844/4885CYP4F2 792/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.